Role of genomic markers in colorectal cancer treatment

Journal of Clinical Oncology

Volumn 23, Issue 20, 2005, Pages 4545-4552

  Allen, Wendy L ^a   Johnston, Patrick G ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA TOPOISOMERASE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GEFITINIB; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PROTEIN P53; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TUMOR MARKER; VATALANIB; XERODERMA PIGMENTOSUM GROUP D PROTEIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; PLATINUM COMPLEX;

CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG MECHANISM; DRUG RECEPTOR BINDING; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MONOTHERAPY; ONCOGENE K RAS; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR BINDING; REVIEW; TREATMENT RESPONSE; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; GENOME; ISOLATION AND PURIFICATION; METABOLISM; MORTALITY; ONCOGENE; PREDICTION AND FORECASTING;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; ONCOGENES; ORGANOPLATINUM COMPOUNDS; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 22844431902     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.19.752     Document Type: Review

References (83)

1. Johnston PG, Lenz HJ, Leichman CG, et al: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55:1407-1412, 1995
2. Edler D, Blomgren H, Allegra CJ, et al: Immunohistochemical determination of thymidylate synthase in colorectal cancer-methodological studies. Eur J Cancer 33:2278-2281, 1997
3. Lenz HJ, Danenberg KD, Leichman CG, et al: p53 and thymidylate synthase expression in untreated stage II colon cancer: Associations with recurrence, survival, and site. Clin Cancer Res 4:1227-1234, 1998
4. Takebe N, Zhao SC, Ural AU, et al: Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells. Cancer Gene Ther 8: 966-973, 2001
5. Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322-1327, 2000
6. Marsh S, McLeod HL: Thymidylate synthase pharmacogenetics in colorectal cancer. Clin Colorectal Cancer 1:1751-81, 2001
7. Kawakami K, Omura K, Kanehira E, et al: Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 19:3249-3252, 1999
8. Metzger R, Danenberg K, Leichman CG, et al: High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 4:2371-2376, 1998
9. Takebayashi Y, Miyadera K, Akiyama S, et al: Expression of thymidine phosphorylase in human gastric carcinoma. Jpn J Cancer Res 87:288-295, 1996
10. Tsuji T, Sawai T, Takeshita H, et al: Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer. Cancer Chemother Pharmacol 54:531-536, 2004
11. Tsuji T, Sawai T, Takeshita H, et al: Tumor dihydropyrimidine dehydrogenase in stage II and III colorectal cancer: Low level expression is a beneficial marker in oral-adjuvant chemotherapy, but is also a predictor for poor prognosis in patients treated with curative surgery alone. Cancer Lett 204:97-104, 2004
12. Tang R, Wang JY, Fan CW, et al: p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: An analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy. Cancer Lett 210:101-109, 2004
13. Ahnen DJ, Feigl P, Quan G, et al: Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group study. Cancer Res 58: 1149-1158, 1998
14. Shirota Y, Stoehlmacher J, Brabender J, et al: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19:4298-4304, 2001
15. Park DJ, Stoehlmacher J, Zhang W, et al: A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61:8654-8658, 2001
16. Jansen WJ, Zwart B, Hulscher ST, et al: CPT-11 in human colon-cancer cell lines and xenografts: Characterization of cellular sensitivity determinants. Int J Cancer 70:335-340, 1997
17. Kern SE, Fearon ER, Tersmette KW, et al: Clinical and pathological associations with allelic loss in colorectal carcinoma. JAMA 261:3099-3103, 1989
18. Liu ZG, Baskaran R, Lea-Chou ET, et al: Three distinct signalling responses by murine fibroblasts to genotoxic stress. Nature 384:273-276, 1996
19. Buglioni S, D'Agnano I, Vasselli S, et al: p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy. Am J Clin Pathol 116:360-368, 2001
20. Gervaz P, Bouzourene H, Cerottini JP, et al: Dukes B colorectal cancer: Distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis Colon Rectum 44:364-373, 2001
21. Bouzourene H, Gervaz P, Cerottini JP, et al: p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur J Cancer 36:1008-1015, 2000
22. Allegra CJ, Paik S, Colangelo LH, et al: Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 21:241-250, 2003
23. Giatromanolaki A, Stathopoulos GP, Tsiobanou E, et al: Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma. Cancer 86:1421-1430, 1999
24. Soong R, Grieu F, Bobbins P, et al: p53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res 3:1405-1411, 1997
25. Bhatavdekar JM, Patel DD, Chikhlikar PR, et al: Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma. Dis Colon Rectum 44:523-533, 2001
26. Shibata D, Reale MA, Lavin P, et al: The DCC protein and prognosis in colorectal cancer. N Engl J Med 335:1727-1732, 1996
27. Lanza G, Matteuzzi M, Gafa R, et al: Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer 79:390-395, 1998
28. Watanabe T, Wu TT, Catalano PJ, et al: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344:1196-1206, 2001
29. Fearon ER, Cho KR, Nigro JM, et al: Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247:49-56, 1990
30. Maesawa C, Tamura G, Nishizuka S, et al: MAD-related genes on 18q21.1, Smad2 and Smad4, are altered infrequently in esophageal squamous cell carcinoma. Jpn J Cancer Res 88:340-343, 1997
31. Hahn SA, Schutte M, Hoque AT, et al: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350-353, 1996
32. Remvikos Y, Muleris M, Salmon RJ, et al: Colorectal carcinogenesis: From chromosomal evolution pathways to molecular pathogenesis. Cancer Genet Cytogenet 93:63-73, 1997
33. Chai SM, Zeps N, Shearwood AM, et al: Screening for defective DNA mismatch repair in stage II and III colorectal cancer patients. Clin Gastroenterol Hepatol 2:1017-1025, 2004
34. Gryfe R, Kim H, Hsieh ET, et al: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342:69-77, 2000
35. Lim SB, Jeyong SY, Lee MR, et al: Prognostic significance of microsatellite instability in sporadic colorectal cancer. Int J Colorectal Dis 19:533-537, 2004
36. Roberts AB, Flanders KC, Heine UI, et al: Transforming growth factor-beta: Multifunctional regulator of differentiation and development. Philos Trans R Soc Lond B Biol Sci 327:145-154, 1990
37. Massague J, Cheifetz S, Boyd FT, et al: TGF-beta receptors and TGF-beta binding proteoglycans: Recent progress in identifying their functional properties. Ann N Y Acad Sci 593:59-72, 1990
38. Shull MM, Ormsby I, Kier AB, et al: Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359:693-699, 1992
39. Kulkarni AB, Huh CG, Becker D, et al: Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 90:770-774, 1993
40. Benhattar J, Losi L, Chaubert P, et al: Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 104: 1044-1048, 1993
41. Lee JC, Wang ST, Lai MD, et al: K-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers. Anticancer Res 16:3839-3844, 1996
42. Andreyev HJ, Norman AR, Cunningham D, et al: Kirsten ras mutations in patients with colorectal cancer: The multicenter "RASCAL" study. J Natl Cancer Inst 90:675-684, 1998
43. Andreyev HJ, Norman AR, Cunningham D, et al: Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study. Br J Cancer 85:692-696, 2001
44. Johnston PG, Kaye S: Capecitabine: A novel agent for the treatment of solid tumors. Anticancer Drugs 12:639-646, 2001
45. Giacchetti S, Perpoint B, Zidani R, et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147, 2000
46. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
47. Houghton JA, Tillman DM, Harwood FG: Ratio of 2′-deoxyadenosine- 5′-triphosphate/ thymidine-5′-triphosphate influences the commitment of human colon carcinoma cells to thymineless death. Clin Cancer Res 1:723-730, 1995
48. Lehman NL: Future potential of thymidylate synthase inhibitors in cancer therapy. Expert Opin Investig Drugs 11:1775-1787, 2002
49. Johnston PG, Drake JC, Trepel J, et al: Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 52:4306-4312, 1992
50. Johnston PG, Fisher ER, Rockette HE, et al: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12:2640-2647, 1994
51. Edler D, Kressner U, Ragnhammar P, et al: Immunohistochemically detected thymidylate synthase in colorectal cancer: An independent prognostic factor of survival. Clin Cancer Res 6:488-492, 2000
52. Marsh S, McKay JA, Cassidy J, et al: Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 19:383-386, 2001
53. Diasio RB, Harris BE: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16:215-237, 1989
54. Johnston SJ, Ridge SA, Cassidy J, et al: Regulation of dihydropyrimidine dehydrogenase in colorectal cancer. Clin Cancer Res 5:2566-2570, 1999
55. Boudny V, Vrana O, Gaucheron F, et al: Biophysical analysis of DNA modified by 1,2-diaminocyclohexane platinum(II) complexes. Nucleic Acids Res 20:267-272, 1992
56. Adjei AA: A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. Br J Clin Pharmacol 48:265-277, 1999
57. Reardon JT, Vaisman A, Chaney SG, et al: Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine- platinum (IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 59:3968-3971, 1999
58. Wilson MD, Ruttan CC, Koop BF, et al: ERCC1: A comparative genomic perspective. Environ Mol Mutagen 38:209-215, 2001
59. Sung P, Bailly V, Weber C, et al: Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature 365:852-855, 1993
60. Takimoto CH, Kieffer LV, Arbuck SG: DNA topoisomerase I inhibitors. Cancer Chemother Biol Response Modif 17:80-113, 1997
61. Pommier Y, Kohlhagen G, Bailly C, et al: DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 35:13303-13309, 1996
62. Misset JL, di Palma M, Delgado M, et al: Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: Final report after a 16-year median follow-up duration. J Clin Oncol 14:1136-1145, 1996
63. Rivory LP, Bowles MR, Robert J, et al: Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 52:1103-1111, 1996
64. Hsiang YH, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722-1726, 1988
65. Zwick E, Hackel PO, Prenzel N, et al: The EGF receptor as central transducer of heterologous signalling systems. Trends Pharmacol Sci 20:408-412, 1999
66. Ciardiello F: Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 60:25-32, 41-42, 2000 (suppl 1)
67. Salomon DS, Normanno N, Ciardiello F, et al: The role of amphiregulin in breast cancer. Breast Cancer Res Treat 33:103-114, 1995
68. Mayer A, Takimoto M, Fritz E, et al: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 71:2454-2460, 1993
69. McKay JA, Murray LJ, Curran S, et al: Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 38:2258-2264, 2002
70. Meropol NJ, Berlin J, Hecht JR: Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 22:2003
71. Cascinu S, Staccioli MP, Gasparini G, et al: Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 6:2803-2807, 2000
72. Ishigami SI, Arii S, Furutani M, et al: Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 78:1379-1384, 1998
73. Morgan B, Thomas AL, Drevs J, et al: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. J Clin Oncol 21:3955-3964, 2003
74. Arango D, Wilson AJ, Shi Q, et al: Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 91:1931-1946, 2004
75. Mariadason JM, Arango D, Shi Q, et al: Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 63:8791-8812, 2003
76. Golub TR, Slonim DK, Tamayo P, et al: Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 286:531-537, 1999
77. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
78. Beer DG, Kardia SL, Huang CC, et al: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8:816-824, 2002
79. Gordon GJ, Jensen RV, Hsiao LL, et al: Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst 95:598-605, 2003
80. Bertucci F, Finetti P, Rougemont J, et al: Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 64:8558-8565, 2004
81. Alon U, Barkai N, Notterman DA, et al: Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci USA 96:6745-6750, 1999
82. Bertucci F, Salas S, Eysteries S, et al: Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 23:1377-1391, 2004
83. Wang Y, Jatkoe T, Zhang Y, et al: Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 22:1564-1571, 2004